GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovacor Inc (AMEX:RCOR) » Definitions » Net Cash per Share

Renovacor (Renovacor) Net Cash per Share : $2.31 (As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Renovacor Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Renovacor's Net Cash per Share for the quarter that ended in Sep. 2022 was $2.31.

The historical rank and industry rank for Renovacor's Net Cash per Share or its related term are showing as below:

RCOR' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.62   Med: 1.21   Max: 3.08
Current: 1.39

During the past 2 years, the highest Price-to-Net-Cash Ratio of Renovacor was 3.08. The lowest was 0.62. And the median was 1.21.

RCOR's Price-to-Net-Cash is not ranked
in the Biotechnology industry.
Industry Median: 4.07 vs RCOR: 1.39

Renovacor Net Cash per Share Historical Data

The historical data trend for Renovacor's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renovacor Net Cash per Share Chart

Renovacor Annual Data
Trend Dec20 Dec21
Net Cash per Share
0.31 3.06

Renovacor Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Net Cash per Share Get a 7-Day Free Trial Premium Member Only 2.94 3.06 3.50 3.26 2.31

Competitive Comparison of Renovacor's Net Cash per Share

For the Biotechnology subindustry, Renovacor's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Renovacor's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Renovacor's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Renovacor's Price-to-Net-Cash falls into.



Renovacor Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Renovacor's Net Cash per Share for the fiscal year that ended in Dec. 2021 is calculated as

Net Cash per Share (A: Dec. 2021 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(78.79-27.455-0)/16.756
=3.06

Renovacor's Net Cash per Share for the quarter that ended in Sep. 2022 is calculated as

Net Cash per Share (Q: Sep. 2022 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(53.713-15.034-0)/16.7694
=2.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Renovacor  (AMEX:RCOR) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Renovacor Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Renovacor's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Renovacor (Renovacor) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 8142, Greenwich, CT, USA, 06836
Renovacor Inc is a preclinical stage gene therapy company developing a pipeline of innovative and proprietary AAV-based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Its therapeutic focus is on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy.
Executives
Joseph S Carroll officer: Chief Accounting Officer C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Gregory F Covino director C/O RICHARD W DAVIES HUBBELL INC, 684 DERBY MILFORD RD, ORANGE CT 06477
Joan Lau director C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Benz Edward J. Jr director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Needham Thomas E. Jr. director MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Frederick W Driscoll officer: Chief Financial Officer
Jonas Grossman director 17 STREET, SUITE 1600, NEW YORK NY 10004
Gbolahan Amusa director 17 STATE STREET 21 FLOOR, NEW YORK NY 10004
Magdalene Cook director, officer: Chief Executive Officer C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Matthew Killeen officer: Chief Scientific Officer C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Rtw Master Fund, Ltd. 10 percent owner C/O WALKERS CORPORATE LIMITED, 190 ELGIN AVENUE, GEORGE TOWN, GRAND CAYMAN E9 KY1-9008
Roderick Wong 10 percent owner C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Marc Semigran officer: Chief Medical Officer C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Wendy F Dicicco officer: Interim CFO

Renovacor (Renovacor) Headlines